Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
S&P 500 Down 1.5%; Dow Falls Over 550 Points
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 450 points on Tuesday.
The Dow traded down 1.68% to 32,868.40 while the NASDAQ fell 1.31% to 11,523.25. The S&P 500 also fell, dropping, 1.55% to 3,985.47.
US Stocks Mixed Ahead Of Powell Testimony; Dick’s Sporting Goods Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 20 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.03% to 33,420.92 while the NASDAQ rose 0.18% to 11,697.05. The S&P 500 also fell, dropping, 0.04% to 4,046.93.
Piper Sandler Maintains Overweight on Cara Therapeutics, Lowers Price Target to $13
Piper Sandler analyst David Amsellem maintains Cara Therapeutics (NASDAQ:CARA) with a Overweight and lowers the price target from $25 to $13.
Nutanix, Cara Therapeutics, Tremor International And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Cara Therapeutics Q4 EPS $(0.56) Misses $(0.32) Estimate, Sales $3.26M Miss $16.25M Estimate
Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.32) by 75 percent. This is a 11.11 percent increase over losses of $(0.63) per share from
Earnings Scheduled For March 6, 2023
Companies Reporting Before The Bell
• Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter.
Needham Reiterates Buy on Cara Therapeutics, Maintains $26 Price Target
Needham analyst Joseph Stringer reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $26 price target.